FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080686146> ?p ?o ?g. }

• W2080686146 endingPage "362" @default.
• W2080686146 startingPage "358" @default.
• W2080686146 abstract "Molecular tumour profiling is one way in which effective targeted cancer treatment regimes might be developed. Two groups report significant developments in this direction. Bild et al. studied gene expression patterns that reflect the activation of various oncogenic (cancer-causing) signal transduction pathways. Using combinations of these pathway signatures, they predict which patients with breast, lung or ovarian cancer have a particularly poor prognosis. The ability to identify molecular pathways that are deregulated in a particular cancer in this way might be used to predict its sensitivity to specific therapeutic drugs. Solit et al. studied tumour cells with mutations in the RAS and BRAF genes, thought to cause cancer at least in part by activating the MEK/ERK signalling pathway. They show that tumours with the BRAF mutation, but not RAS, are highly sensitive to PD0325901, an MEK inhibitor that is in early-stage clinical trials in patients with melanoma, colon, breast and lung cancers. So by testing for the presence of BRAF mutations it may be possible to identify those patients most likely to benefit from this type of drug. The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members1. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either ‘wild-type’ cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype." @default.
• W2080686146 created "2016-06-24" @default.
• W2080686146 creator A5000845600 @default.
• W2080686146 creator A5001392592 @default.
• W2080686146 creator A5001449157 @default.
• W2080686146 creator A5010776820 @default.
• W2080686146 creator A5010918073 @default.
• W2080686146 creator A5018999020 @default.
• W2080686146 creator A5031609787 @default.
• W2080686146 creator A5055048393 @default.
• W2080686146 creator A5057346782 @default.
• W2080686146 creator A5060228803 @default.
• W2080686146 creator A5075174884 @default.
• W2080686146 creator A5080635562 @default.
• W2080686146 creator A5085810259 @default.
• W2080686146 creator A5088968401 @default.
• W2080686146 date "2005-11-06" @default.
• W2080686146 modified "2023-10-17" @default.
• W2080686146 title "BRAF mutation predicts sensitivity to MEK inhibition" @default.
• W2080686146 cites W125601491 @default.
• W2080686146 cites W1494491432 @default.
• W2080686146 cites W1967835627 @default.
• W2080686146 cites W1988911160 @default.
• W2080686146 cites W1992494265 @default.
• W2080686146 cites W1992772703 @default.
• W2080686146 cites W2014719030 @default.
• W2080686146 cites W2015009944 @default.
• W2080686146 cites W2026389696 @default.
• W2080686146 cites W2035936653 @default.
• W2080686146 cites W2041098455 @default.
• W2080686146 cites W2050422354 @default.
• W2080686146 cites W2077309295 @default.
• W2080686146 cites W2105006863 @default.
• W2080686146 cites W2106465904 @default.
• W2080686146 cites W2108958930 @default.
• W2080686146 cites W2109363337 @default.
• W2080686146 cites W2118033606 @default.
• W2080686146 cites W2123885531 @default.
• W2080686146 cites W2126553652 @default.
• W2080686146 cites W2163188200 @default.
• W2080686146 cites W2165712565 @default.
• W2080686146 cites W2336656340 @default.
• W2080686146 cites W363037004 @default.
• W2080686146 doi "https://doi.org/10.1038/nature04304" @default.
• W2080686146 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3306236" @default.
• W2080686146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16273091" @default.
• W2080686146 hasPublicationYear "2005" @default.
• W2080686146 type Work @default.
• W2080686146 sameAs 2080686146 @default.
• W2080686146 citedByCount "1217" @default.
• W2080686146 countsByYear W20806861462012 @default.
• W2080686146 countsByYear W20806861462013 @default.
• W2080686146 countsByYear W20806861462014 @default.
• W2080686146 countsByYear W20806861462015 @default.
• W2080686146 countsByYear W20806861462016 @default.
• W2080686146 countsByYear W20806861462017 @default.
• W2080686146 countsByYear W20806861462018 @default.
• W2080686146 countsByYear W20806861462019 @default.
• W2080686146 countsByYear W20806861462020 @default.
• W2080686146 countsByYear W20806861462021 @default.
• W2080686146 countsByYear W20806861462022 @default.
• W2080686146 countsByYear W20806861462023 @default.
• W2080686146 crossrefType "journal-article" @default.
• W2080686146 hasAuthorship W2080686146A5000845600 @default.
• W2080686146 hasAuthorship W2080686146A5001392592 @default.
• W2080686146 hasAuthorship W2080686146A5001449157 @default.
• W2080686146 hasAuthorship W2080686146A5010776820 @default.
• W2080686146 hasAuthorship W2080686146A5010918073 @default.
• W2080686146 hasAuthorship W2080686146A5018999020 @default.
• W2080686146 hasAuthorship W2080686146A5031609787 @default.
• W2080686146 hasAuthorship W2080686146A5055048393 @default.
• W2080686146 hasAuthorship W2080686146A5057346782 @default.
• W2080686146 hasAuthorship W2080686146A5060228803 @default.
• W2080686146 hasAuthorship W2080686146A5075174884 @default.
• W2080686146 hasAuthorship W2080686146A5080635562 @default.
• W2080686146 hasAuthorship W2080686146A5085810259 @default.
• W2080686146 hasAuthorship W2080686146A5088968401 @default.
• W2080686146 hasBestOaLocation W20806861462 @default.
• W2080686146 hasConcept C104317684 @default.
• W2080686146 hasConcept C121608353 @default.
• W2080686146 hasConcept C143998085 @default.
• W2080686146 hasConcept C184235292 @default.
• W2080686146 hasConcept C2776087337 @default.
• W2080686146 hasConcept C2776256026 @default.
• W2080686146 hasConcept C2777658100 @default.
• W2080686146 hasConcept C2778472372 @default.
• W2080686146 hasConcept C2781230642 @default.
• W2080686146 hasConcept C2781249067 @default.
• W2080686146 hasConcept C501734568 @default.
• W2080686146 hasConcept C502942594 @default.
• W2080686146 hasConcept C530470458 @default.
• W2080686146 hasConcept C54355233 @default.
• W2080686146 hasConcept C57074206 @default.
• W2080686146 hasConcept C62478195 @default.
• W2080686146 hasConcept C71924100 @default.
• W2080686146 hasConcept C86803240 @default.
• W2080686146 hasConceptScore W2080686146C104317684 @default.
• W2080686146 hasConceptScore W2080686146C121608353 @default.

• next